Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Change in Receivables (2022 - 2025)

TriSalus Life Sciences' Change in Receivables history spans 4 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 340.72% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 4.94%, while the annual FY2025 figure was $1.6 million, 4.94% down from the prior year.
  • Change in Receivables reached $1.6 million in Q4 2025 per TLSIW's latest filing, up from -$497000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.6 million in Q4 2025 to a low of -$736000.0 in Q4 2022.
  • Average Change in Receivables over 4 years is $353538.5, with a median of $366000.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: soared 1965.71% in 2024, then plummeted 341.26% in 2025.
  • A 4-year view of Change in Receivables shows it stood at -$736000.0 in 2022, then surged by 168.21% to $502000.0 in 2023, then dropped by 28.09% to $361000.0 in 2024, then soared by 340.72% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Change in Receivables are $1.6 million (Q4 2025), -$497000.0 (Q3 2025), and $174000.0 (Q2 2025).